1. Home
  2. LQDA vs EVV Comparison

LQDA vs EVV Comparison

Compare LQDA & EVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
    SELLHOLDBUYas of a day ago
  • EVV
    SELLHOLDBUYas of a day ago
  • Stock Information
  • Founded
  • LQDA 2004
  • EVV 2003
  • Country
  • LQDA United States
  • EVV United States
  • Employees
  • LQDA N/A
  • EVV N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • EVV Finance/Investors Services
  • Sector
  • LQDA Health Care
  • EVV Finance
  • Exchange
  • LQDA Nasdaq
  • EVV Nasdaq
  • Market Cap
  • LQDA 1.3B
  • EVV 1.2B
  • IPO Year
  • LQDA 2018
  • EVV N/A
  • Fundamental
  • Price
  • LQDA $14.50
  • EVV $10.04
  • Analyst Decision
  • LQDA Strong Buy
  • EVV
  • Analyst Count
  • LQDA 7
  • EVV 0
  • Target Price
  • LQDA $26.67
  • EVV N/A
  • AVG Volume (30 Days)
  • LQDA 859.7K
  • EVV 323.7K
  • Earning Date
  • LQDA 05-12-2025
  • EVV 01-01-0001
  • Dividend Yield
  • LQDA N/A
  • EVV 9.66%
  • EPS Growth
  • LQDA N/A
  • EVV N/A
  • EPS
  • LQDA N/A
  • EVV N/A
  • Revenue
  • LQDA $15,610,000.00
  • EVV N/A
  • Revenue This Year
  • LQDA N/A
  • EVV N/A
  • Revenue Next Year
  • LQDA $208.28
  • EVV N/A
  • P/E Ratio
  • LQDA N/A
  • EVV N/A
  • Revenue Growth
  • LQDA N/A
  • EVV N/A
  • 52 Week Low
  • LQDA $8.26
  • EVV $8.52
  • 52 Week High
  • LQDA $16.99
  • EVV $10.07
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 45.13
  • EVV 38.92
  • Support Level
  • LQDA $13.50
  • EVV $10.00
  • Resistance Level
  • LQDA $15.57
  • EVV $10.21
  • Average True Range (ATR)
  • LQDA 0.71
  • EVV 0.07
  • MACD
  • LQDA -0.28
  • EVV -0.03
  • Stochastic Oscillator
  • LQDA 30.86
  • EVV 15.00

Stock Price Comparison Chart: LQDA vs EVV

LQDA
EVV
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025024681012141618LQDA VS EVV

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest

Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund may, as a secondary objective, also seek capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure among others.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use